News

Quanta Announces IND Clearance by U.S. FDA for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates

– IND for QTX3544 is third for Quanta within one year – – Initiated combination portion of Phase 1 clinical…

12 months ago

Transcarent To Acquire Accolade

Combined company creates industry leading platform with more than 1,400 employer and payer clients, with shared focus on consumer empowerment…

12 months ago

Foresight Diagnostics Provides 2025 Outlook and 2024 Year in Review

- Achieved 100% revenue growth versus prior year – - Received Investigational Device Exemption approval from the FDA for the…

12 months ago

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicineWill provide key regulatory…

12 months ago

SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer

DENVER, Jan. 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary…

12 months ago

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating…

12 months ago

Safety Shot to Acquire Yerbaé Brands Corp., adding approximately $12 Million to Annual Revenue and Creating a Potential Force in Wellness and Functional Beverages

Yerbaé is a scalable, growth-oriented complementary brand with a large and growing addressable marketYerbaé creates clean, simple, and delicious plant-based…

12 months ago

Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine…

12 months ago

Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial

SARASOTA, FL, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage…

12 months ago

SELLAS Announces Key Business Objectives for 2025

- Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009:…

12 months ago